Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Alcohol Use Disorder
Interventions: Psilocybin, Inactive Placebo, Supportive therapy sessions; Drug · Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Delirium, Agitation
Interventions: Risperidone, Trazodone, Placebo; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Infections, Bacterial
Interventions: 500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: ASC42, Placebo; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Major Depressive Disorder, Healthy Volunteer
Interventions: Basimglurant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Acute Pain, Molar, Molar, Third, Surgery, Oral
Interventions: LY4515100, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type 1 Diabetes Mellitus, Diabetes
Interventions: REMD-477, Placebo Comparator; Biological
Lead sponsor: REMD Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: San Diego, California • St Louis, Missouri

Conditions: Alcohol Use Disorders (AUD)
Interventions: Mifepristone 600-mg/day or placebo for a week; Drug
Lead sponsor: Brown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Depression
Interventions: Apimostinel Infusion, Intravenous, Cognitive Training, Sham Training, Isotonic Solution, Intravenous; Drug · Behavioral
Lead sponsor: Rebecca Price; Other
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Autism Spectrum Disorders
Interventions: Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin; Drug
Lead sponsor: Linmarie Sikich; Other
Eligibility: 3 Years to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • White Plains, New York + 3 more

Conditions: Fragile X Syndrome
Interventions: Gaboxadol, Placebo; Drug
Lead sponsor: Craig Erickson; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Placebo (NNC0662-0419); Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Tetrodotoxin, placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetes Mellitus, Type 1
Interventions: LY3532226, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Thyroid Eye Disease
Interventions: AMG 732, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more

Conditions: Pain
Interventions: Novel Ibuprofen, Acetaminophen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Subjects
Interventions: ASP5354, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Rheumatoid Arthritis
Interventions: ARRY-371797, p38 inhibitor; oral, Placebo; oral; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Tuscaloosa, Alabama • Peoria, Arizona • Little Rock, Arkansas + 4 more

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Healthy
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Postoperative Pain, Inguinal Hernia
Interventions: Bupivacaine Collagen Sponge, placebo collagen sponge; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Severe Sepsis
Interventions: BMS-986189, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Asthma
Interventions: Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Search by objective public record fields.

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Mifepristone for the Prevention of Relapses of Alcohol Drinking

Apimostinel + Automated Neurocognitive Training for Depression

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

A Study of ARRY-371797 in Patients With Rheumatoid Arthritis

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma